WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 563164
CAS#: 1002789-86-7
Description: TZ9 is an inhibitor of Rad6B expressing human breast cancer cell lines MDA-MB-231 and MCF-7. It is also the first competitive E2-ligase inhibitor that acts by blocking thioester formation.
MedKoo Cat#: 563164
Name: TZ9
CAS#: 1002789-86-7
Chemical Formula: C17H14N6O4
Exact Mass: 366.1077
Molecular Weight: 366.33
Elemental Analysis: C, 55.74; H, 3.85; N, 22.94; O, 17.47
Synonym: TZ9; TZ-9; TZ 9; SMI#9;
IUPAC/Chemical Name: (4-Amino-6-anilino-1,3,5-triazin-2-yl)methyl 4-nitrobenzoate
InChi Key: RRRDZFQRNJTKHL-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H14N6O4/c18-16-20-14(21-17(22-16)19-12-4-2-1-3-5-12)10-27-15(24)11-6-8-13(9-7-11)23(25)26/h1-9H,10H2,(H3,18,19,20,21,22)
SMILES Code: O=C(OCC1=NC(N)=NC(NC2=CC=CC=C2)=N1)C3=CC=C([N+]([O-])=O)C=C3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
The following data is based on the product molecular weight 366.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Nethi SK, P NAA, Rico-Oller B, Rodríguez-Diéguez A, Gómez-Ruiz S, Patra CR. Design, synthesis and characterization of doped-titanium oxide nanomaterials with environmental and angiogenic applications. Sci Total Environ. 2017 Dec 1;599-600:1263-1274. doi: 10.1016/j.scitotenv.2017.05.005. Epub 2017 May 15. PubMed PMID: 28525935.
2: Kothayer H, Spencer SM, Tripathi K, Westwell AD, Palle K. Synthesis and in vitro anticancer evaluation of some 4,6-diamino-1,3,5-triazine-2-carbohydrazides as Rad6 ubiquitin conjugating enzyme inhibitors. Bioorg Med Chem Lett. 2016 Apr 15;26(8):2030-4. doi: 10.1016/j.bmcl.2016.02.085. Epub 2016 Mar 2. PubMed PMID: 26965855; PubMed Central PMCID: PMC4808444.
3: Kothayer H, Elshanawani AA, Abu Kull ME, El-Sabbagh OI, Shekhar MP, Brancale A, Jones AT, Westwell AD. Design, synthesis and in vitro anticancer evaluation of 4,6-diamino-1,3,5-triazine-2-carbohydrazides and -carboxamides. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6886-9. doi: 10.1016/j.bmcl.2013.09.087. Epub 2013 Oct 6. PubMed PMID: 24153206.
